Oxidative Stress in Systemic Lupus Erythematosus Causes Inflammation and Cellular Damage

Shahad F.  Obeid; Wasnaa J.  Mohammad; Israa Abass  Rashed

Shahad F. Obeid Department of Chemistry, College of Sciences, University of Baghdad, Baghdad, Iraq
Wasnaa J. Mohammad Department of Basic Sciences , College of Nursing, University of Baghdad, Baghdad, Iraq
Israa Abass Rashed College of Basic Education, Mustansiriyah University, Baghdad, Iraq.

Keywords: Systemic Lupus Erythematosus (SLE), Autoantibodies, Inflammation, Oxidative Stress, Immunomodulation, Autoimmune Disease

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs, driven by a combination of genetic, environmental, and hormonal factors leading to immunological dysregulation. The disease is characterized by the production of autoantibodies, inflammation, and end-organ damage, with oxidative stress playing a significant role by inducing functional changes in DNA, lipids, and proteins. Current understanding of SLE pathophysiology highlights the importance of oxidative stress biomarkers in predicting disease progression and guiding treatment. Despite available treatments like corticosteroids and immunosuppressants, there remains a need for more effective therapies with fewer side effects. This research aims to investigate the relationship between oxidative stress and SLE progression, utilizing biomarkers to improve early diagnosis and treatment decisions. By analyzing oxidatively modified molecules in SLE patients, the study seeks to enhance our understanding of disease mechanisms and identify new therapeutic targets to reduce morbidity and mortality.

Downloads

Download data is not yet available.

References

G. C. Tsokos, "Systemic Lupus Erythematosus," *N. Engl. J. Med.*, vol. 365, pp. 2110–2121, 2011.

V. R. Moulton, A. Suarez-Fueyo, E. Meidan, H. Li, M. Mizui, and G. C. Tsokos, "Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective," *Trends Mol. Med.*, vol. 23, no. 7, pp. 615-635, Jul. 2017, doi: 10.1016/j.molmed.2017.05.006. PMID: 28623084; PMCID: PMC5650102.

B. Dema and N. Charles, "Autoantibodies in SLE: Specificities, Isotypes and Receptors," *Antibodies (Basel)*, vol. 5, no. 1, p. 2, Jan. 2016, doi: 10.3390/antib5010002. PMID: 31557984; PMCID: PMC6698872.

M. J. Podolska, M. H. Biermann, C. Maueröder, J. Hahn, and M. Herrmann, "Inflammatory Etiopathogenesis of Systemic Lupus Erythematosus: An Update," *J. Inflamm. Res.*, vol. 8, pp. 161-171, Aug. 2015, doi: 10.2147/JIR.S70325. PMID: 26316795; PMCID: PMC4548750.

Y. M. Bouts, D. F. Wolthuis, M. F. Dirkx, et al., "Apoptosis and NET Formation in the Pathogenesis of SLE," *Autoimmunity*, vol. 45, no. 8, pp. 597–601, 2012.

I. B. Murimi-Worstell, D. H. Lin, H. Nab, et al., "Association Between Organ Damage and Mortality in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis," *BMJ Open*, vol. 10, p. e031850, 2020, doi: 10.1136/bmjopen-2019-031850.

M. Gayed, S. Bernatsky, R. Ramsey-Goldman, A. Clarke, and C. Gordon, "Lupus and Cancer," *Lupus*, vol. 18, no. 6, pp. 479-485, 2009.

S. Ajeganova, I. Hafström, and J. Frostegård, "Patients with SLE Have Higher Risk of Cardiovascular Events and Mortality in Comparison with Controls with the Same Levels of Traditional Risk Factors and Intima-Media Measures, Which is Related to Accumulated Disease Damage and Antiphospholipid Syndrome: A Case–Control Study Over 10 Years," *Lupus Sci. Med.*, vol. 8, p. e000454, 2021, doi: 10.1136/lupus-2020-000454.

L. Durcan and M. Petri, "Immunomodulators in SLE: Clinical Evidence and Immunologic Actions," *J. Autoimmun.*, vol. 74, pp. 73-84, 2016, doi: 10.1016/j.jaut.2016.06.010.

K. Lerang, I.-M. Gilboe, D. Steinar Thelle, and J. T. Gran, "Mortality and Years of Potential Life Loss in Systemic Lupus Erythematosus: A Population-Based Cohort Study," *Lupus*, vol. 23, pp. 1546–1552, 2014.

C. Besler, T. F. Lüscher, and U. Landmesser, "Molecular Mechanisms of Vascular Effects of High-Density Lipoprotein: Alterations in Cardiovascular Disease," *EMBO Mol. Med.*, vol. 4, pp. 251–268, 2012.

A. Kontush, et al., "Structure of HDL: Particle Subclasses and Molecular Components," *Handb. Exp. Pharmacol.*, vol. 224, pp. 3–51, 2015.

A. Kontush, M. Lhomme, and M. J. Chapman, "Unraveling the Complexities of the HDL Lipidome," *J. Lipid Res.*, vol. 54, pp. 2950–2963, 2013.

S. Y. Kim, M. Yu, E. E. Morin, J. Kang, M. J. Kaplan, and A. Schwendeman, "High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy," *Arthritis Rheumatol.*, vol. 72, no. 1, pp. 20-30, Jan. 2020, doi: 10.1002/art.41059. PMID: 31350818; PMCID: PMC6935404.

C. Soni and B. Reizis, "Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects," *Front. Immunol.*, vol. 10, 2019, doi: 10.3389/fimmu.2019.01601.

W.-H. Shao and P. L. Cohen, "The Role of Tyrosine Kinases in Systemic Lupus Erythematosus and Their Potential as Therapeutic Targets," *Expert Rev. Clin. Immunol.*, vol. 10, no. 5, pp. 573-582, 2014, doi: 10.1586/1744666X.2014.893827.

M. K. Crow, "Etiology and Pathogenesis of Systemic Lupus Erythematosus," in *Kelly's Textbook of Rheumatology*, G. S. Firestein, R. C. Budd, S. E. Gabriel, I. B. McInnes, and J. R. O'Dell, Eds. Philadelphia, PA: Elsevier Saunders, 2013, pp. 1269–1282.

G. C. Tsokos, "Systemic Lupus Erythematosus," *N. Engl. J. Med.*, vol. 365, pp. 2110–2121, 2011.

J. E. Lewis, S. M. Fu, and F. Gaskin, "Autoimmunity, End Organ Damage, and the Origin of Autoantibodies and Autoreactive T Cells in Systemic Lupus Erythematosus," *Discov. Med.*, vol. 15, no. 81, pp. 85-92, Feb. 2013. PMID: 23449110; PMCID: PMC3725807.